Guggenheim Reiterates Buy on Neumora Therapeutics, Maintains $14 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 86.2%

Neg 0% Neu 86.2% Pos 0%

Guggenheim analyst Yatin Suneja reiterates Neumora Therapeutics (NASDAQ:NMRA) with a Buy and maintains $14 price target.